Immediate Impact
21 standout
Citing Papers
Fibrosis in IBD: from pathogenesis to therapeutic targets
2024 Standout
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements
2024 Standout
Works of M.F. Alvisi being referenced
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer
2022
BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC)
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| M.F. Alvisi | 142 | 53 | 76 | 67 | 18 | 257 | |
| Yoo‐Na Kim | 74 | 47 | 34 | 81 | 34 | 245 | |
| Alberto Ranghiero | 99 | 86 | 56 | 22 | 26 | 284 | |
| Katayoun Taghavi | 101 | 36 | 22 | 38 | 28 | 293 | |
| G. Thomas | 72 | 63 | 36 | 68 | 18 | 287 | |
| Wanyuan Cui | 91 | 62 | 105 | 32 | 29 | 272 | |
| William W. Terry | 84 | 120 | 38 | 18 | 21 | 290 | |
| Sandro Tognazzo | 129 | 31 | 41 | 71 | 15 | 335 | |
| L. Dreyer | 56 | 55 | 67 | 39 | 21 | 325 | |
| Gaili Chen | 159 | 59 | 40 | 7 | 17 | 325 | |
| Olivia D. Lara | 102 | 44 | 21 | 22 | 27 | 177 |
All Works
Login with ORCID to disown or claim papers
Loading papers...